RxDoctor Payments Data

John Wright, MD

Neurology · Des Moines, IANPI 1679550503

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,938 and has fallen 56.8% since, to $837 in 2025.

$8,809in general payments, 2019–2025

Across 359 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Jazz Pharmaceuticals Inc.$904
  • TG Therapeutics, Inc.$682
  • Biogen$676
  • Novartis$598
  • Harmony Biosciences LLC$574
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$701%
  • Food & beverage$8,62298%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,809 in reported general payments places this provider in the 85th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$57,672
Medicare patients
355
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5012$316,927
Emgality SyringeGalcanezumab-Gnlm13$9,238
Modafinil29$1,659
Levetiracetam33$1,149
Ropinirole Hcl24$1,126
Zonisamide20$1,103
Oxcarbazepine13$975
Memantine Hcl34$798
Gabapentin42$657
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$599
Donepezil Hcl72$596
Clonazepam30$382
Lamotrigine21$367
ClopidogrelClopidogrel Bisulfate38$188
Trazodone Hcl29$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$16$15527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 neurology providers in Iowa.

Other neurology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →